Alnylam Pharmaceuticals, Inc. (ALNY) reported record sales of $492 million for their flagship product, Amvuttra, in Q2 2025, exceeding expectations. This led to an increase in revenue guidance for 2025 to $2.18–$2.28 billion, with total projected net revenues between $2.65–$2.8 billion, boosting the company’s market valuation above $50 billion.

The quarterly success of Amvuttra has positioned it as a leading treatment for transthyretin amyloidosis (ATTR) cardiomyopathy, with over 1,400 patients on therapy by the end of the quarter. Priced at $476,000 annually, it is gaining popularity as a first-line therapy, supported by commercial and Medicare payers.

In addition to their commercial achievements, Alnylam Pharmaceuticals, Inc. is advancing their pipeline with RNAi therapeutics for cardiovascular diseases like hypertension. They have also presented promising data on the sustained benefits of Amvuttra in ATTR cardiomyopathy, showcasing their commitment to innovation and development in the field.

Read more at Yahoo Finance: Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance